REFERENCES


22. Early Breast Cancer Trialists’


150


57. Dehdashti F, Mortimer JE, Trinkaus K, et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast


137. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project...


151. Robertson JFR. Fulvestrant (Faslodex®)—How to Make a Good Drug Better. 2007; 12: 774-84.


expression is a biological marker for androgen sensitivitv in high grade serous epithelial ovarian cancer. *Gynecol Oncol* 2012; 124: 142-7.


198. Tan DS, Rothermundt C, Thomas K, et al. “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and


